Early data indicate efficacy of Targovax immuno-oncology candidate

2 February 2017

Shares in Norwegian immuno-oncology specialists Targovax (TRVX: OL) leapt by a third today after the company announced encouraging clinical data from an ongoing study.

The data relate to the first cohort of patients in its Phase I/II clinical trial into prospective targeted immunotherapeutic TG01.

Data from this patient cohort showed that 68% of evaluated patients had survived two years following resection, when treated with TG01 in combination with the current chemotherapeutic standard of care, gemcitabine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK